Advertisement
Research ArticleArticle

CYP2B6 and CYP2C19 as the Major Enzymes Responsible for the Metabolism of Selegiline, a Drug Used in the Treatment of Parkinson's Disease, as Revealed from Experiments with Recombinant Enzymes

Mats Hidestrand, Mikael Oscarson, Jarmo S. Salonen, Leena Nyman, Olavi Pelkonen, Miia Turpeinen and Magnus Ingelman-Sundberg
Drug Metabolism and Disposition November 2001, 29 (11) 1480-1484;

Article Information

vol. 29 no. 11 1480-1484
PubMed 
11602525
Published By 
American Society for Pharmacology and Experimental Therapeutics
Print ISSN 
0090-9556
Online ISSN 
1521-009X
History 
  • Received March 28, 2001
  • Accepted August 6, 2001
  • Published online November 1, 2001.
Copyright & Usage 
The American Society for Pharmacology and Experimental Therapeutics

Author Information

  1. Mats Hidestrand1,
  2. Mikael Oscarson1,
  3. Jarmo S. Salonen2,
  4. Leena Nyman2,
  5. Olavi Pelkonen3,
  6. Miia Turpeinen3 and
  7. Magnus Ingelman-Sundberg1
  1. 1Division of Molecular Toxicology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden (M.H., M.O., M.I.-S.); 2Orion Pharma, Preclinical and Clinical R & D, Turku, Finland (J.S.S., L.N.); and 3Department of Pharmacology and Toxicology, University of Oulu, Oulu, Finland (O.P., M.T.)
  1. Dr. Magnus Ingelman-Sundberg, Division of Molecular Toxicology, IMM Karolinska Institutet, 171 77 Stockholm, Sweden. E-mail: magnus.ingelman-sundberg{at}imm.ki.se
View Full Text

Statistics from Altmetric.com

Article usage

Article usage: August 2017 to March 2023

AbstractFullPdf
Aug 201701710
Sep 20175910
Oct 20173169
Nov 201710356
Dec 2017383
Jan 20182267
Feb 2018101112
Mar 201822317
Apr 2018102417
May 201861721
Jun 20184187
Jul 201841516
Aug 20181153
Sep 20182182
Oct 20188173
Nov 20185257
Dec 201839118
Jan 20191811
Feb 20192431
Mar 20192821
Apr 20193052
May 20191654
Jun 20192022
Jul 20191711
Aug 20191673
Oct 20193600
Nov 20194931
Dec 20193284
Jan 20202510
Feb 20202000
Mar 20202353
May 20202410
Jun 20202000
Jul 20201321
Aug 20201221
Sep 20201300
Oct 20203510
Nov 20204935
Dec 20203712
Jan 202115223
Feb 202133144
Mar 20212632
Apr 20211310
May 202159143
Jun 20211480
Jul 2021931
Aug 202115110
Sep 20211220
Oct 20211150
Nov 20212772
Dec 20212541
Jan 20222360
Feb 20221343
Mar 20221911
Apr 20222481
May 20221421
Jun 20221341
Jul 20221711
Aug 20221110
Sep 20221582
Oct 202218102
Nov 20222722
Dec 2022710
Jan 20232641
Feb 2023610
Mar 20231320

Back to top

In this issue

Download PDF
Article Alerts
Email Article
Citation Tools

Research ArticleArticle

CYP2B6 and CYP2C19 as the Major Enzymes Responsible for the Metabolism of Selegiline, a Drug Used in the Treatment of Parkinson's Disease, as Revealed from Experiments with Recombinant Enzymes

Mats Hidestrand, Mikael Oscarson, Jarmo S. Salonen, Leena Nyman, Olavi Pelkonen, Miia Turpeinen and Magnus Ingelman-Sundberg
Drug Metabolism and Disposition November 1, 2001, 29 (11) 1480-1484;
Reddit logo Twitter logo Facebook logo Mendeley logo

Jump to section

Advertisement